Your browser doesn't support javascript.
loading
Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A PostHoc Analysis from the CREDENCE Trial.
Oshima, Megumi; Neuen, Brendon L; Li, JingWei; Perkovic, Vlado; Charytan, David M; de Zeeuw, Dick; Edwards, Robert; Greene, Tom; Levin, Adeera; Mahaffey, Kenneth W; De Nicola, Luca; Pollock, Carol; Rosenthal, Norman; Wheeler, David C; Jardine, Meg J; Heerspink, Hiddo J L.
Afiliação
  • Oshima M; The George Institute for Global Health, University of New South Wales Sydney, Sydney, Australia.
  • Neuen BL; Department of Nephrology and Laboratory Medicine, Kanazawa University, Kanazawa, Japan.
  • Li J; The George Institute for Global Health, University of New South Wales Sydney, Sydney, Australia.
  • Perkovic V; The George Institute for Global Health, University of New South Wales Sydney, Sydney, Australia h.j.lambers.heerspink@umcg.nl.
  • Charytan DM; The George Institute for Global Health, University of New South Wales Sydney, Sydney, Australia.
  • de Zeeuw D; Nephrology Division, School of Medicine and Langone Medical Center, New York University, New York, New York.
  • Edwards R; Baim Institute for Clinical Research, Boston, Massachusetts.
  • Greene T; Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
  • Levin A; Janssen Research & Development, LLC, Raritan, New Jersey.
  • Mahaffey KW; Division of Biostatistics, Department of Population Health Sciences, University of Utah, Salt Lake City, Utah.
  • De Nicola L; Division of Nephrology, University of British Columbia, Vancouver, Canada.
  • Pollock C; Stanford Center for Clinical Research, Department of Medicine, Stanford University School of Medicine, Stanford, California.
  • Rosenthal N; Department of Advanced Medical and Surgical Sciences, Nephrology and Dialysis Unit, University Vanvitelli, Naples, Italy.
  • Wheeler DC; Kolling Institute of Medical Research, Sydney Medical School, University of Sydney, Royal North Shore Hospital, St Leonards, Australia.
  • Jardine MJ; Janssen Research & Development, LLC, Raritan, New Jersey.
  • Heerspink HJL; The George Institute for Global Health, University of New South Wales Sydney, Sydney, Australia.
J Am Soc Nephrol ; 31(12): 2925-2936, 2020 12.
Article em En | MEDLINE | ID: mdl-32998938
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Diabetes Mellitus Tipo 2 / Albuminúria / Insuficiência Renal Crônica / Canagliflozina / Inibidores do Transportador 2 de Sódio-Glicose Tipo de estudo: Clinical_trials / Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Doenças Cardiovasculares / Diabetes Mellitus Tipo 2 / Albuminúria / Insuficiência Renal Crônica / Canagliflozina / Inibidores do Transportador 2 de Sódio-Glicose Tipo de estudo: Clinical_trials / Diagnostic_studies / Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2020 Tipo de documento: Article